Immunology
BioTools Innovator opens 2022 applications
BioTools Innovator is now accepting applications from startups and emerging growth companies for its second annual accelerator program. The program aims to advance innovation in life science and improve human health by accelerating the growth of best-in-class startups that are developing and commercializing biotechnology products, platforms, and services. Read More
Istari moves quickly to validate its poliovirus vaccine-based cancer immunotherapy
It's been a busy year for Istari Oncology, which is developing its PVSRIPO viral immunotherapy based on the poliovirus vaccine. Istari's President and CEO Matt Stober and Chief Medical Officer Dr. Garrett Nichols recently spoke with ScienceBoard about the progress of PVSRIPO for the treatment of solid tumors. Read More
Asgard Therapeutics raises seed funding for novel in vivo cancer immunotherapy
Asgard Therapeutics, a private biotech startup based in Lund, Sweden, has raised 6 million euros (about $6.8 million) in seed financing, co-led by Novo Holdings, a global life science investor based in Hellerup, Denmark. Read More
Technology upgrades needed to address future pandemics, GAO report says
Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability Office (GAO) report. Read More
Myxoma virus enters as an exciting preclinical cancer immunotherapy platform
A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting. Read More
5 takeaways from SITC 2021
WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting. Read More
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting. Read More
Why one industry veteran launched a new cancer immunotherapy company
WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch of NKILT Therapeutics. Read More
Where is the immunotherapy field headed after COVID-19?
WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting. Read More
Is the accelerated approval process working for cancer immunotherapies?
WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting. Read More
Conferences
Cell and Gene Therapy Manufacturing and Commercialization Europe 2021
December 1-3
Vienna Austria
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter